ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.002,38
1,51%
S&P 500
5.713,64
1,70%
Dow Jones
42.025,19
1,26%
Euro vs US Dollar
1,11691
0,09%
Bitcoin
63.730,20
1,24%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Esperion Therapeutics Inc (ESPR)

  7. Esperion Therapeutics Inc (ESPR) News

ESPR

Esperion Therapeutics (ESPR)

Esperion Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ESPR
DatumZeitQuelleÜberschriftSymbolFirma
18/09/202422h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
18/09/202422h11Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/09/202422h02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/09/202421h28Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/09/202421h20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
05/09/202414h00GlobeNewswire Inc.Esperion to Participate in Upcoming 2024 Cantor Global Healthcare ConferenceNASDAQ:ESPREsperion Therapeutics Inc
03/09/202414h00GlobeNewswire Inc.Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)NASDAQ:ESPREsperion Therapeutics Inc
26/08/202414h00GlobeNewswire Inc.Esperion to Participate in Upcoming H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:ESPREsperion Therapeutics Inc
20/08/202422h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
19/08/202421h50Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
12/08/202422h33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ESPREsperion Therapeutics Inc
12/08/202422h08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ESPREsperion Therapeutics Inc
12/08/202413h21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
12/08/202412h00GlobeNewswire Inc.Esperion Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNASDAQ:ESPREsperion Therapeutics Inc
12/08/202411h47IH Market NewsU.S. Futures Steady as Markets Await Key Inflation Data, Oil Prices ClimbNASDAQ:ESPREsperion Therapeutics Inc
07/08/202422h30GlobeNewswire Inc.Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)NASDAQ:ESPREsperion Therapeutics Inc
05/08/202422h34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
25/07/202414h00GlobeNewswire Inc.Esperion to Report Second Quarter 2024 Financial Results on August 12NASDAQ:ESPREsperion Therapeutics Inc
24/07/202414h00GlobeNewswire Inc.Esperion to Participate in Upcoming BTIG Biotech ConferenceNASDAQ:ESPREsperion Therapeutics Inc
19/07/202414h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
19/07/202414h29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/07/202421h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
17/07/202421h11Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
16/07/202414h00GlobeNewswire Inc.New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their ArteriesNASDAQ:ESPREsperion Therapeutics Inc
28/06/202413h00GlobeNewswire Inc.Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest FacilityNASDAQ:ESPREsperion Therapeutics Inc
18/06/202421h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
18/06/202421h09Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ESPREsperion Therapeutics Inc
28/05/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ESPREsperion Therapeutics Inc
24/05/202422h18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
24/05/202422h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ESPREsperion Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ESPR

Kürzlich von Ihnen besucht

NYSE
MRK
Merck
FX
EURGBP
Euro vs Sterling
COIN
DOGEUSD
Dogecoin
TG
TUI1
Tui
COIN
ETHUSD
Ethereum
USOTC
BNPQY
BNP Paribas (QX)
CCOM
US100
US Tech 100
COIN
ADAUSD
Cardano
COIN
XRPUSD
Ripple
USOTC
RHHBY
Roche (QX)
TG
D7G
Nel ASA
NYSE
KO
Coca Cola
DBI
TDXP
Tec DAX
NYSE
JPM
JP Morgan Chase
DBI
DAX
DAX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten